The study named Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes (DEVOTE; CT.gov identifier: NCT01959529), a trial involving 7637 patients with stated CVD and a mean diabetes duration of 16 years [8], confirmed the CV safety of insulin degludec when compared with insulin glargine. Here, INS is linked to type 2 diabetes mellitus.